Insulin Degludec
Injection
To Be Discontinued Active (discontinuing) — Day 297
High impact — Sole-source drug with no supply currently available from this manufacturer.
FDA shortage record
- Substance
- Insulin Degludec
- Manufacturers / suppliers
-
- Novo Nordisk Pharma, Inc.
- Novo Nordisk, Inc.
- Dosage form
- Injection
- Presentation
- Insulin Degludec, Injection, 3 mL Insulin Degludec 100 units/mL (U-100) FlexTouch® (NDC 73070-403-15)
- Route(s)
- SUBCUTANEOUS
- Therapeutic category
- Endocrinology/Metabolism
- Package NDC
73070-403-15- Initially posted
- 07/21/2025
- Days on shortage list
- 297
- Discontinued
- 07/21/2025
- Current FDA status
- To Be Discontinued
- Shortage entries (current dataset)
- 1 record for Insulin Degludec
Reason and context
Unbranded Insulin Degludec 3 mL U-100 FlexTouch® will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.
Manufacturer contact
Per the FDA record, the manufacturer's contact for supply inquiries is 609-987-5800.
If you're affected by this shortage
- Talk to your prescribing clinician or pharmacist about therapeutic alternatives. Do not switch medications on your own.
- Ask your pharmacy to check supply across multiple wholesalers and other branches.
- Check current pharmacy pricing and availability via GoodRx (affiliate link).
- Report a continuing supply problem to FDA via the FDA Drug Shortages contact form.
Sources
- FDA Drug Shortages database, accessed via the openFDA Drug Shortages API.
- FDA Structured Product Label (SPL set ID
c1be283d-4b1d-4996-b2a7-4488dbff3037). - FDA UNII identifier:
54Q18076QB. - See the Drug Shortage Tracker methodology for sourcing, update cadence, normalization rules, and limits.
Important
This page reproduces publicly available FDA shortage data for informational purposes only. It is not medical advice and does not establish a clinician-patient relationship. Shortage status changes frequently; verify directly with your pharmacist or the FDA Drug Shortages site before making any treatment decision.